CG Oncology Inc.

About CG Oncology Inc.

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing oncolytic immunotherapies for patients with bladder cancer. Their mission is to enable urologic cancer patients to benefit from innovative therapies, enhancing their dignity and quality of life.

Products & Services

Cretostimogene Grenadenorepvec:An investigational engineered oncolytic immunotherapy (OIT) for bladder cancer, particularly in BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). It has shown clinical benefit as a monotherapy and in combination with other therapies in clinical trials, though it is not yet approved by regulatory agencies.

Specialties

Oncolytic Immunotherapy Bladder Cancer Treatment Bladder-Sparing Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 238000000 MR: - FA: $238.0 million FAN: 238000000	D: 2024-12-16 FD: 2024-12-16	5 investors
2	RT: Public Offering T: - FT: Public Offering	A: 204400000 MR: - FA: $204.4 million FAN: 204400000	D: 2024-12-12 FD: 2024-12-12	5 investors
3	RT: Public Offering T: - FT: Public Offering	A: 7300000 MR: - FA: 7,300,000 shares FAN: 7300000	D: 2024-12-11 FD: 2024-12-11	5 investors
4	RT: Initial Public Offering (IPO) T: - FT: Initial Public Offering (IPO)	A: 437000000 MR: - FA: $437.0 million FAN: 437000000	D: 2024-01-30 FD: 2024-01-30	4 investors
5	RT: Crossover T: - FT: Crossover	A: 105000000 MR: - FA: 105 million FAN: 105000000	D: 2023-08-02 FD: 2023-08-02	11 investors

Public Offering Latest

2024-12-16

$238.0M

5 investors (Pro only)

Public Offering 2024-12-12

$204.4M

Public Offering 2024-12-11

$7.3M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Arthur Kuan

Chairman & Chief Executive Officer

A

Ambaw Bellete

President & Chief Operating Officer

V

Vijay Kasturi, MD

Chief Medical Officer

S

Swapnil Bhargava

Chief Technical Officer

J

Josh Patterson, Esq.

General Counsel & Chief Compliance Officer

S

Susan E. Graf, RPh, MBA

Senior Advisor & Entrepreneur in Residence, Locust Walk

View 12 more team members with Pro

Unlock Full Team Directory

Recent News

CG Oncology Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised